Altamont Pharma Acquisition Corp
Status: Stalled
U=S+W
W=S@11.50
| IPO Proceeds, $M | $100.00M |
|---|---|
| IPO Date | * |
| CEO | Mark Pearson |
| Left Lead | Chardan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Companies that are developing assets in biopharma and medical technology |
| IPO Geography | Europe |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
ALTP
ALTPU
ALTP/W
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Altamont Pharma Acquisition Corp:
- Structure and cap table
- 8 directors & officers
- 2 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Mark Pearson | 55 | President and Chief Executive Officer and Chairman |
| Rhozel Ocampo | 25 | Senior Director of Finance |
| Yitai Tang, Ph.D. | 44 | Senior Investment Officer and Analyst |
| Gayathri Srinivasan | 28 | Senior Analyst |
| Sharon Tetlow | 60 | Director |
| John D. Harkey, Jr. | 60 | Director |
| Jay Shepard | 63 | Director |
| Lisa Walters-Hoffert | 62 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | BR | 10,000,000 | units |
| B. Riley FBR | 1 | ||
| 10,000,001 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 2 filings.